Shopping Cart
- Remove All
- Your shopping cart is currently empty
Carbimazole (Athyromazole) is an Imidazolium thyroid antagonist, which is rapidly transformed into MMI in vivo and can be converted into methidazole in vitro, and can be used in the study of Graves' disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
500 mg | $46 | In Stock | |
1 mL x 10 mM (in DMSO) | $48 | In Stock |
Description | Carbimazole (Athyromazole) is an Imidazolium thyroid antagonist, which is rapidly transformed into MMI in vivo and can be converted into methidazole in vitro, and can be used in the study of Graves' disease. |
In vivo | Once absorbed by the human body, Carbimazole is metabolized into Methimazole, which exerts anti-thyroid activity. It specifically targets conditions such as hyperthyroidism (excessive production of thyroid hormones) and thyrotoxicosis (thyroid inflammation). |
Kinase Assay | In vitro kinase assays: with purified proteins, recombinant S6 protein and recombinant active P70S6K are incubated in 1x kinase buffer with various amount of HCQ or RAD001 in the presence (25 μM) or absence of ATP for 30 minutes at 30°C. Total and phosphorylated S6 at ser235/236 and ser240/244 are detected by western analysis using phosphospecific antibodies. Note that recombinant GST-tagged S6 (53 kd) is distinguished from endogenous S6 (32 kd) on the western blot. |
Alias | Neomercazole, Carbimazol, Athyromazole |
Molecular Weight | 186.23 |
Formula | C7H10N2O2S |
Cas No. | 22232-54-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 12 mg/mL (64.4 mM) DMSO: 60 mg/mL (322.18 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.